MiR-873/PD-L1 axis regulates the stemness of breast cancer cells

被引:119
作者
Gao, Lanlan [1 ,2 ]
Guo, Qianqian [1 ,2 ]
Li, Xiaoman [3 ]
Yang, Xuan [1 ,2 ]
Ni, Haiwei [1 ,2 ]
Wang, Ting [1 ,2 ]
Zhao, Qiong [1 ,2 ]
Liu, Hai [1 ,2 ]
Xing, Yingying [1 ,2 ]
Xi, Tao [1 ,2 ]
Zheng, Lufeng [1 ,2 ]
机构
[1] China Pharmaceut Univ, Sch Life Sci & Technol, Nanjing 210009, Peoples R China
[2] China Pharmaceut Univ, Jiangsu Key Lab Carcinogenesis & Intervent, Nanjing 210009, Peoples R China
[3] Nanjing Univ Chinese Med, Sch Pharm, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing 210023, Jiangsu, Peoples R China
来源
EBIOMEDICINE | 2019年 / 41卷
基金
中国博士后科学基金;
关键词
miR-873; PD-L1; Cancer stem cells; Drug resistance; PI3K/Akt; ERK1/2; PD-L1; EXPRESSION; TUMOR-SUPPRESSOR; IFN-GAMMA; TAMOXIFEN RESISTANCE; DRUG-RESISTANCE; TARGETING CDK3; B7-H1; METASTASIS; CHEMORESISTANCE; PROGRESSION;
D O I
10.1016/j.ebiom.2019.02.034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Breast cancer stem cells have self-renewal capability and are resistant to conventional chemotherapy. PD-L1 could promote the expression of stemness markers (OCT4 and Nanog) in breast cancer stem cells. However, the mechanisms by which PD-L1 regulates the stemness of breast cancer cells and PD-L1 is regulated in breast cancer cells are still unclear. Methods: Lentivirus infectionwas used to construct stable cell lines. The correlation between PD-L1 and stemness markers expression was evaluated in clinical samples. Additionally, luciferase reporter assay combined with RNA-Fluorescence in situ hybridization (RNA-FISH) and RNA-binding protein immunoprecipitation (RIP) assays were used to verify the direct binding of miR-873 on PD-L1. Furthermore, flowcytometry, mammosphere formation combined with nude mouse tumor xenograftmodel were carried out to examine the effects ofmiR-873/PDL1 axis on the stemness of breast cancer cells. Finally, MTT assay was performed to determine the effects of miR873/ PD-L1 axis on drug resistance. Findings: PD-L1 expression was positively correlated with the expression of stemness markers, and overexpression of PD-L1 contributed to chemoresistance and stemness-like properties in breast cancer cells via activating PI3K/Akt and ERK1/2 pathways. Mechanistically, miR-873 inhibited PD-L1 expression through directly binding to its 3'-untranslated region (UTR), and miR-873 attenuated the stemness and chemoresistance of breast cancer cells which was dependent on PD-L1 and the downstream PI3K/Akt and ERK1/2 signaling. Notably, the promotion of PD-L1 on the stemness and chemoresistance was enhanced by recombinant PD-1 (rPD-1), this effect was attenuated by PD-1/PD-L1 inhibitor. Interpretation: miR-873/PD-L1 regulatory axis might serve as a therapeutic target to enhance the chemosensitivity and eliminate the stemness of breast cancer cells. Fund: This work was supported by the National Nature Science Foundation of China, No. 81702957, China Postdoctoral Science Foundation, No. 2017M620230, the Postdoctoral Research Funding Scheme of Jiangsu Province (2017), No. 1701197B, and the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions. (c) 2019 The Authors. Published by Elsevier B. V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:395 / 407
页数:13
相关论文
共 49 条
  • [1] IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
    Abiko, K.
    Matsumura, N.
    Hamanishi, J.
    Horikawa, N.
    Murakami, R.
    Yamaguchi, K.
    Yoshioka, Y.
    Baba, T.
    Konishi, I.
    Mandai, M.
    [J]. BRITISH JOURNAL OF CANCER, 2015, 112 (09) : 1501 - 1509
  • [2] Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance
    AlHossiny, Midrar
    Luo, Linlin
    Frazier, William R.
    Steiner, Noriko
    Gusev, Yuriy
    Kallakury, Bhaskar
    Glasgow, Eric
    Creswell, Karen
    Madhavan, Subha
    Kumar, Rakesh
    Upadhyay, Geeta
    [J]. CANCER RESEARCH, 2016, 76 (11) : 3376 - 3386
  • [3] Cancer stem cells: problems for therapy?
    Alison, Malcolm R.
    Lim, Susan M. L.
    Nicholson, Linda J.
    [J]. JOURNAL OF PATHOLOGY, 2011, 223 (02) : 147 - 161
  • [4] PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation
    Almozyan, Sheema
    Colak, Dilek
    Mansour, Fatmah
    Alaiya, Ayodele
    Al-Harazi, Olfat
    Qattan, Amal
    Al-Mohanna, Falah
    Al-Alwan, Monther
    Ghebeh, Hazem
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2017, 141 (07) : 1402 - 1412
  • [5] Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells
    Alsuliman, Abdullah
    Colak, Dilek
    Al-Harazi, Olfat
    Fitwi, Hanaa
    Tulbah, Asma
    Al-Tweigeri, Taher
    Al-Alwan, Monther
    Ghebeh, Hazem
    [J]. MOLECULAR CANCER, 2015, 14
  • [6] Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis
    Black, Madison
    Barsoum, Ivraym B.
    Truesdell, Peter
    Cotechini, Tiziana
    Macdonald-Goodfellow, Shannyn K.
    Petroff, Margaret
    Siemens, D. Robert
    Koti, Madhuri
    Craig, Andrew W. B.
    Graham, Charles H.
    [J]. ONCOTARGET, 2016, 7 (09) : 10557 - 10567
  • [7] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2455 - 2465
  • [8] Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a-LCOR axis
    Celia-Terrassa, Toni
    Liu, Daniel D.
    Choudhury, Abrar
    Hang, Xiang
    Wei, Yong
    Zamalloa, Jose
    Alfaro-Aco, Raymundo
    Chakrabarti, Rumela
    Jiang, Yi-Zhou
    Koh, Bong Ihn
    Smith, Heath A.
    DeCoste, Christina
    Li, Jun-Jing
    Shao, Zhi-Ming
    Kang, Yibin
    [J]. NATURE CELL BIOLOGY, 2017, 19 (06) : 711 - +
  • [9] Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
    Chen, Limo
    Gibbons, Don L.
    Goswami, Sangeeta
    Cortez, Maria Angelica
    Ahn, Young-Ho
    Byers, Lauren A.
    Zhang, Xuejun
    Yi, Xiaohui
    Dwyer, David
    Lin, Wei
    Diao, Lixia
    Wang, Jing
    Roybal, Jonathon D.
    Patel, Mayuri
    Ungewiss, Christin
    Peng, David
    Antonia, Scott
    Mediavilla-Varela, Melanie
    Robertson, Gordon
    Jones, Steve
    Suraokar, Milind
    Welsh, James W.
    Erez, Baruch
    Wistuba, Ignacio I.
    Chen, Lieping
    Peng, Di
    Wang, Shanshan
    Ullrich, Stephen E.
    Heymach, John V.
    Kurie, Jonathan M.
    Qin, F. Xiao-Feng
    [J]. NATURE COMMUNICATIONS, 2014, 5
  • [10] Cui J, 2015, ONCOGENE, V34, P3895, DOI 10.1038/onc.2014.430